FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.
What happened
FDA reviewed altRx’s website in May 2026 and found it offered compounded semaglutide and tirzepatide products. FDA said the pictured labels name “altRx” as if altRx were the compounder when it is not, and the site used claims such as “clinically proven” for compounded products that are not FDA-approved.
What FDA found
FDA said the website’s pictured labels show “altRx” as if altRx made the compounded semaglutide and tirzepatide products, but it is not the compounder.
FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)FDA said claims that the compounded products are “clinically proven” are false or misleading because compounded drug products are not FDA-approved.
FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]FDA said putting these products into interstate commerce is a prohibited act because of the misleading claims.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]FDA said receiving, delivering, or offering to deliver these products in interstate commerce is also prohibited.
FD&C Act § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells altRx to email a written response to FDA’s Office of Compounding Quality and Compliance within 15 business days with corrective steps and documentation, including identifying the entities that produce the compounded drugs, giving sample labeling, and addressing or removing the misleading website claims.
Who should pay attention
- telehealth and online pharmacy sites selling compounded GLP-1 drugs
- compounders whose products are promoted by resellers or marketers
- pharmacies and brands using 'clinically proven' claims for compounded drugs
This is a summary. Read the original letter on fda.gov.